• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Clinical Development
    • Biologics
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending T
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Clinical Development
    • Biologics
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

hepatitis D

Layoffs
Biotech

Vir gains 3 T-cell engagers from Sanofi, lays off 25% of staff

The “strategic restructuring” is designed to push resources into Vir’s hepatitis programs “and focus on the highest near-term value opportunities.”
James Waldron Aug 2, 2024 6:12am
business strategy game play plan football soccer

Vir keeps pressure on Gilead with midphase hepatitis D data

Jun 5, 2024 8:52am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2024 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings